Case series of BRAF-mutated advanced melanoma treated with encorafenib plus binimetinib combination therapy

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Advanced melanoma with BRAF mutations presents treatment challenges.
• The efficacy of encorafenib plus binimetinib (E+B) as second-line therapy is not well-established.
• Understanding treatment outcomes for E+B in later lines of therapy is crucial.

Purpose of the Study:

• To evaluate the efficacy and safety of encorafenib plus binimetinib (E+B) in patients with BRAF-mutated advanced melanoma receiving second-line or later treatment.
• To compare the objective response rate (ORR) of E+B in this cohort with first-line targeted therapy outcomes.
• To assess the safety profile and tolerability of E+B in a real-world setting.

Main Methods:

• Retrospective analysis of 22 cases of BRAF-mutated advanced melanoma treated with E+B.
• Calculation of objective response rate (ORR) for the entire cohort and the second-line and beyond subgroup.
• Evaluation of overall survival (OS) and progression-free survival (PFS).
• Assessment of severe adverse events (SAEs).

Main Results:

• The overall objective response rate (ORR) was 68.4%.
• For the second-line and beyond cohort, the ORR was 73.3%, comparable to first-line targeted therapy.
• Overall survival and progression-free survival were worse compared to a previous clinical trial.
• The incidence of severe adverse events was higher than previously reported, but E+B was deemed well-tolerated.

Conclusions:

• Encorafenib plus binimetinib (E+B) demonstrates significant efficacy as a second-line or later treatment for BRAF-mutated advanced melanoma.
• The therapeutic effect of E+B in later lines is comparable to first-line targeted therapy, with a notable ORR.
• Despite a higher incidence of severe adverse events, E+B is considered a well-tolerated regimen for advanced melanoma.